BR112012020556A8 - uso de sequência-líder pten-longa para liberação transmembrana de moléculas - Google Patents
uso de sequência-líder pten-longa para liberação transmembrana de moléculasInfo
- Publication number
- BR112012020556A8 BR112012020556A8 BR112012020556A BR112012020556A BR112012020556A8 BR 112012020556 A8 BR112012020556 A8 BR 112012020556A8 BR 112012020556 A BR112012020556 A BR 112012020556A BR 112012020556 A BR112012020556 A BR 112012020556A BR 112012020556 A8 BR112012020556 A8 BR 112012020556A8
- Authority
- BR
- Brazil
- Prior art keywords
- molecules
- pten
- charge
- leader sequence
- long leader
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
uso de sequência líder pten-long para transporte transmembrana de moléculas. uma composição para a entrega de moléculas de carga através das membranas biológicas é fornecida compreendendo um peptídeo (i) compreendendo os resíduos de aminoácidos consecutivos com a sequência descrita em seq id no 1 para o transporte de uma molécula de carga através de uma membrana biológica e a moléculka de carga (ii), em que a molécula de carga não é um péptido compreendendo os resíduos de aminoácidos possuindo a sequência apresentada na seq id no 4. métodos de transporte de moléculas de carga através das membranas biológicas também são fornecidos. métodos de tratamento de um tumor, câncer, um distúrbio metabólico, e um dist´purbio cardiovascular são também fornecidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33837710P | 2010-02-17 | 2010-02-17 | |
PCT/US2011/025312 WO2011103339A1 (en) | 2010-02-17 | 2011-02-17 | Use of pten-long leader sequence for transmembrane delivery of molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012020556A2 BR112012020556A2 (pt) | 2017-01-10 |
BR112012020556A8 true BR112012020556A8 (pt) | 2018-01-02 |
Family
ID=44483307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012020556A BR112012020556A8 (pt) | 2010-02-17 | 2011-02-17 | uso de sequência-líder pten-longa para liberação transmembrana de moléculas |
Country Status (9)
Country | Link |
---|---|
US (1) | US9074011B2 (pt) |
EP (1) | EP2536420A4 (pt) |
JP (1) | JP6009360B2 (pt) |
CN (1) | CN102844043B (pt) |
AU (1) | AU2011218037B2 (pt) |
BR (1) | BR112012020556A8 (pt) |
CA (4) | CA3017701C (pt) |
MX (1) | MX2012009565A (pt) |
WO (1) | WO2011103339A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2752590C (en) | 2009-02-17 | 2017-08-22 | The Trustees Of Columbia University In The City Of New York | Identification of extracellular form of pten that can be used to treat tumors |
US9375473B2 (en) | 2010-02-19 | 2016-06-28 | Cornell Research Foundation, Inc. | Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases |
KR20180066237A (ko) * | 2015-10-19 | 2018-06-18 | 유니버시티 오브 매사추세츠 | 항-암 및 항-염증 치료제 및 이의 방법 |
CN110087662A (zh) * | 2016-07-29 | 2019-08-02 | 俄亥俄州国家创新基金会 | 用溶瘤病毒表达pten-long |
CN109022462B (zh) | 2017-06-08 | 2021-12-21 | 中山大学附属第一医院 | 一种PTEN基因的上游开放阅读框31aa-uORF核苷酸及其编码的多肽的应用 |
CN108504671A (zh) * | 2018-03-28 | 2018-09-07 | 宁波市医疗中心李惠利医院 | 一种PTEN-Long蛋白纯化制备方法 |
CN108484780A (zh) * | 2018-04-16 | 2018-09-04 | 河南大学 | 一种融合蛋白PTEN-L-p53及其应用 |
CN109224075B (zh) * | 2018-08-07 | 2021-11-16 | 浙江大学 | Pten抑制剂在制备治疗1型糖尿病药物中的应用 |
WO2020208609A1 (en) * | 2019-04-12 | 2020-10-15 | Therapten Biosciences Inc. | Compositions and methods to manufacture phosphatase and tensin homolog (pten) fusions |
CN112877309B (zh) * | 2021-02-19 | 2022-05-17 | 北京大学 | 一种N端延长型PTEN亚型PTENζ蛋白及其编码基因和应用 |
CN113666998B (zh) * | 2021-08-10 | 2023-03-21 | 北京大学 | 一种具有调控神经系统发育功能的PTEN亚型蛋白PTENδ及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6482795B1 (en) | 1997-01-30 | 2002-11-19 | Myriad Genetics, Inc. | Tumor suppressor designated TS10q23.3 |
CA2752590C (en) | 2009-02-17 | 2017-08-22 | The Trustees Of Columbia University In The City Of New York | Identification of extracellular form of pten that can be used to treat tumors |
-
2011
- 2011-02-17 CA CA3017701A patent/CA3017701C/en not_active Expired - Fee Related
- 2011-02-17 EP EP11745260.7A patent/EP2536420A4/en not_active Withdrawn
- 2011-02-17 JP JP2012554034A patent/JP6009360B2/ja not_active Expired - Fee Related
- 2011-02-17 CA CA3017689A patent/CA3017689A1/en not_active Abandoned
- 2011-02-17 CA CA3017717A patent/CA3017717A1/en not_active Abandoned
- 2011-02-17 MX MX2012009565A patent/MX2012009565A/es active IP Right Grant
- 2011-02-17 CN CN201180018210.8A patent/CN102844043B/zh not_active Expired - Fee Related
- 2011-02-17 AU AU2011218037A patent/AU2011218037B2/en not_active Ceased
- 2011-02-17 US US13/579,025 patent/US9074011B2/en not_active Expired - Fee Related
- 2011-02-17 CA CA2790046A patent/CA2790046C/en not_active Expired - Fee Related
- 2011-02-17 WO PCT/US2011/025312 patent/WO2011103339A1/en active Application Filing
- 2011-02-17 BR BR112012020556A patent/BR112012020556A8/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN102844043A (zh) | 2012-12-26 |
AU2011218037B2 (en) | 2016-10-13 |
AU2011218037A1 (en) | 2012-10-04 |
CA3017701A1 (en) | 2011-08-25 |
WO2011103339A1 (en) | 2011-08-25 |
CN102844043B (zh) | 2015-07-29 |
CA2790046C (en) | 2018-10-30 |
US20130171235A1 (en) | 2013-07-04 |
CA2790046A1 (en) | 2011-08-25 |
US9074011B2 (en) | 2015-07-07 |
BR112012020556A2 (pt) | 2017-01-10 |
MX2012009565A (es) | 2014-02-27 |
CA3017717A1 (en) | 2011-08-25 |
EP2536420A1 (en) | 2012-12-26 |
EP2536420A4 (en) | 2016-02-24 |
CA3017689A1 (en) | 2011-08-25 |
JP6009360B2 (ja) | 2016-10-19 |
CA3017701C (en) | 2020-12-15 |
JP2013522168A (ja) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012020556A8 (pt) | uso de sequência-líder pten-longa para liberação transmembrana de moléculas | |
Klaassen et al. | Xenobiotic, bile acid, and cholesterol transporters: function and regulation | |
ES2541217T3 (es) | Diferenciación de células madre mesenquimales | |
ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
AR080669A1 (es) | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina | |
CL2015003199A1 (es) | Peptidos terapeuticos | |
BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
AR080229A1 (es) | Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23) | |
BR112013010855A2 (pt) | luciferases derivadas de oplophorus, novos substratos de coelenterazina e métodos de uso | |
CL2012001539A1 (es) | Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo. | |
CL2012003077A1 (es) | Polipeptido que comprende el decimo dominio de fibronectina tipo iii (10fn3), en donde el dominio 10fn3 se une al dominio 1 o 2 de seroalbumina humana, y donde la vida media del suero del polipéptido en presencia de seroalbumina es al menos 5 veces mayor que en su ausencia; acido nucleico que lo codifica; vector que lo comprende; celula hospedera que lo expresa; composición que lo comprende; y su uso para tratar la diabetes. | |
CL2008003527A1 (es) | Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7 | |
CL2019003426A1 (es) | Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
BR112012010661A2 (pt) | método para tratar insuficiência cardíaca com peptídeos semelhantes à estressecopina | |
CL2008003357A1 (es) | Procedimiento para obtener una solucion de albumina humana con alta capacidad de union de moleculas que comprende una diafiltracion, estabilizacion con nacl y aminoacidos sin adicion de acidos grasos, pasteurizacion y una segunda diafiltracion. | |
ES2542227T3 (es) | Tratamiento de complicaciones vasculares de diabetes | |
BR112012017306A2 (pt) | materiais e métodos para produção de membrana bioinorgânicas que não ocorrem naturalmente associadas e direcionadas à superfície celular | |
WO2011135222A3 (fr) | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles | |
BR112012030084A2 (pt) | peptídeos que se ligam a receptores do fator de crescimento semelhante à insulina tipo 1 | |
CL2019003328A1 (es) | Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer. (divisional solicitud 201703244) | |
NZ596300A (en) | Fviii-derived peptides | |
WO2014111841A3 (en) | Peptide | |
NZ583429A (en) | Peptides and proteins capable of inhibiting and/or preventing mast cell activation | |
CO6311116A2 (es) | Sistema para la expresion de peptidos sobre la superficie bacteriana de escherichia coli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |